

CASE ON/4-32744A

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

George R. Dohmann
Type or print name


Signature

October 1, 2008

Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
CENTRAL FAX CENTER

OCT 01 2008

IN RE APPLICATION OF

Art Unit: 1614

JOSEPH ALEXANDER LASKY

APPLICATION NO: 10/532,297

FILED: AUGUST 24, 2005

FOR: USE OF N-{5-[4-(4-METHYLPIPERAZIOMETHYL)-
BENZOYLAMIDO]-2-METHYLPHENYL}-4-(3-PYRIDYL)-2-
PYRIDINE-AMINE FOR THE TREATMENT OF PULMONARY
HYPERTENSION

MS: Amendment
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

COMMUNICATION

Sir:

A response to the Office action dated April 1, 2008 was filed electronically in a timely manner today, October 1, 2008. The response included a Petition for Extension of time which requested a 3 month extension. However, the undersigned had difficulties paying the extension fee electronically and was advised to submit by facsimile a copy of the Petition for Extension of time, which includes authorization to charge Deposit Account No. 19-0134, which the undersigned is now doing. Attached are a copy of the Petition for Extension of Time (in duplicate along with a copy of the electronic filing receipt for the electronic submission that included the response, EFS ID 4045713.

Respectfully submitted,


George R. Dohmann
Attorney for Applicant
Reg. No. 33,593

Novartis Pharmaceuticals Corp.
Patents Pharma
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7824
Date: October 1, 2008

Acknowledgement Receipt

The USPTO has received your submission at 19:02:19 Eastern Time on 01-OCT-2008 .

No fees have been paid for this submission. Please remember to pay any required fees on time to prevent abandonment of your application.

eFiled Application Information

EFS ID	4045713
Application Number	10532297
Confirmation Number	1063
Title	Use of n-(5-[4-(4-methylpiperaziomethyl)-benzoylamido]-2-methylphenyl)-4-(3-pyridyl)-2-pyridine-amine for the treatment of pulmonary hypertension
First Named Inventor	Joseph Alexander Lasky
Customer Number or Correspondence Address	01095
Filed By	George R. Dohmann
Attorney Docket Number	ON/4-32744A
Filing Date	24-AUG-2005
Receipt Date	01-OCT-2008
Application Type	U.S. National Stage under 35 USC 371

RECEIVED
CENTRAL FAX CENTER
OCT 01 2008

Application Details

Submitted Files	Page Count	Document Description	File Size	Warnings
3274410-08.pdf	7		205646 bytes	◆ PASS
		Document Description	Page Start	Page End
		Extension of Time	1	1
		Amendment/Req. Reconsideration-After Non-Final Reject	2	2
		Claims	3	4
		Applicant Arguments/Remarks Made in an Amendment	5	7
fee-info.pdf	2	Fee Worksheet (PTO-06)	30500 bytes	◆ PASS

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371